Fusen Pharmaceutical Co., Ltd. was listed on the main board of the Hong Kong Stock Exchange in 2018, stock code: 1652.hk. Based on the traditional Chinese medicine industry, the company is committed to building a health industry group integrating traditional Chinese medicine, chemical drugs and biopharmaceutical.
The Chinese patent medicine segment of Fusen pharmaceutical mainly relies on Henan Fusen pharmaceutical, a wholly owned subsidiary, and Weihai life Pharmaceutical Group, a joint-stock company. Among them, Henan Fusen Pharmaceutical Co., Ltd. is a modern comprehensive pharmaceutical enterprise integrating cultivation of herbal, drug R & D, production and sales. Since its establishment in 2003, Fusen pharmaceutical, adhering to the concept of "honesty and trustworthiness, strengthening the foundation, winning the brand and steady development", has been successively awarded the titles of "national leading enterprise of agricultural industrialization" and "excellent private enterprise" and "high-tech enterprise" in Henan Province. Under the background of healthy China, the company will adhere to the business philosophy of "craftsmanship quality, health is happiness" to protect the health of consumers.